anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
CircRNAs play an important role in various physiological and pathological biological processes. Despite their widespread involvement, the function of circRNAs in intermittent hypoxia (IH) remain incompletely understood. This study aims to clarify the molecular mechanism of it in IH. Differentially expressed circRNAs were identified by transcriptome sequencing analysis in intermittent hypoxia (IH) model. GO and KEGG enrichment analys were performed on the identified differentially expressed circRNAs. The circular characteristics of hsa_circ_0081065 in human umbilical vein endothelial cells (HUVECs) were detected by RT-qPCR. The sublocalization of hsa_circ_0081065 was examined by FISH. The effect of hsa_circ_0081065 on endothelial to mesenchymal transition (EndMT) was estimated by detecting the expression of EndMT related markers. Various techniques, including RNA-pull down, RIP, EMSA, dual-luciferase reporter assay and immunofluorescence staining were used to investigate the relationship among hsa_circ_0081065, miR-665 and HIF-1α. A total of 13,304 circRNAs were identified in HUVECs treatment with IH, among which 73 were differentially expressed, including 24 upregulated circRNAs and 49 downregulated circRNAs. Notably, hsa_circ_0081065 demonstrated a significantly upregulation. Hsa_circ_0081065 exhibited the circular characteristics of circRNA and was predominantly localized in the cytoplasm. Knockdown of hsa_circ_0081065 inhibited EndMT. Mechanically, we demonstrated that hsa_circ_0081065 acts as a sponge for miR-665 to up-regulate HIF-1α and exacerbate HIF-1α nuclear translocation in HUVECs. We have demonstrated that hsa_circ_0081065 is significantly upregulated in HUVECs treated with IH. Our findings indicate that hsa_circ_0081065 exacerbates IH-induced EndMT through the regulation of the miR-665/HIF-1α signal axis and facilitating HIF-1α nuclear translocation. These results provide a theoretical basis for considering of EndMT as a potential therapeutic target for OSAHS intervention.
A pill identification system identifies a pill type for a pharmaceutical composition from images of the pharmaceutical composition. The system extracts features from images taken of the pill. The features extracted from the pill image include color, size, shape, and surface features of the pill. In particular, the features include rotation-independent surface features of the pill that enable the pill to be identified from a variety of orientations when the images are taken. The feature vectors are applied to a classifier that determines a pill identification for each image. The pill identification for each image is scored to determine identification for the pharmaceutical composition. Fig. 1 /120 100 120
The incidence of pre-eclampsia is about 2-8%, it is a leading cause of maternal and perinatal mortality and morbidity. Both ACOG (American Congress of Obstetricians and Gynecologists) and NICE (National Institute for Health and Clinical Excellence) guideline advocate the use of traditional screening method, which uses demographic characters and medical history to identify high risk women. This method detects only 35-40% of pre-eclampsia women. Study has shown that combination of maternal factors and biomarkers (uterine artery pulsatility index, placenta growth factor, PlGF; pregnancy associated plasma protein-A, PAPP-A) improves the detection rate.

In Taiwan, the prevalence of pre-eclampsia is about 1.21%. The incidence of pre-eclampsia is correlated with maternal age, with a relative risk of 5.13-fold in women aged 40 and above. Marrying late predisposes these women at high risk of developing pre-eclampsia. Our institution will be implementing first-trimester screening program starting from April 2019, this study aims to evaluate the clinical effectiveness of this screening program in preventing pre-eclampsia.
Aims: This research was aimed at investigating the effects of hypoxia inducible factor-1 alpha (HIF-1α)-mediated DNA methylation enzymes (ten-eleven translocase-2 [TET2] and DNA methyltransferase-3a [DNMT3a]) under hypoxic conditions on S100A6 transcription, thereby promoting the growth and metastasis of lung cancer cells. Methods: The expression of HIF-1α or S100A6 in lung cancer cells was interfered with under normoxic and hypoxic conditions, and the cell proliferative, migratory, and invasive properties were assessed. The mechanism of HIF-1α-regulated TET2 and DNMT3 effects on S100A6 transcription under hypoxic conditions was further investigated. Results: Functionally, S100A6 over-expression promoted lung cancer cell proliferation and metastasis. S100A6 over-expression reversed the inhibitory effects of HIF-1α interference on the proliferation and metastasis of lung cancer cells. S100A6 was induced to express in an HIF-1α-dependent manner under hypoxic conditions, and silencing S100A6 or HIF-1α suppressed lung cancer cell proliferation and metastasis under hypoxic conditions. Further, The Cancer Genome Atlas-lung adenocarcinoma database analysis revealed that S100A6 mRNA levels had a negative correlation with methylation levels. Mechanistically, CpG hypomethylation status in the S100A6 promoter hypoxia response element had an association with HIF-1α induction. TET2 was enriched in S100A6 promoter region of lung cancer cells under hypoxic conditions, whereas DNMT3a enrichment was reduced in S100A6 promoter region. HIF-1α-mediated S100A6 activation was linked to DNMT3a-associated epigenetic inactivation and TET2 activation. Innovation: The activation of HIF-1α-mediated DNA methylation enzymes under hypoxic conditions regulated S100A6 transcription, thereby promoting lung cancer cell growth and metastasis. Conclusion: In lung cancer progression, hypoxia-induced factor HIF-1α combined with DNA methylation modifications co-regulates S100A6 transcriptional activation and promotes lung cancer cell growth and metastasis.
Marginal zone lymphoma (MZL) is a relatively common group of non-Hodgkin's lymphoma (NHL). The incidence rate is only inferior to diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Currently, NCCN guidelines recommend same treatment plan of FL like R-CHOP as the primary treatment for MZL. However, due to the great difference in cell origin and biological characteristics between FL and MZL, some patients can not achieve complete remission or relapse quickly after standard first-line treatment. A number of phase II clinical studies have evaluated the good efficacy of rituximab combined with chemotherapy in the treatment of MZL. Previous studies have shown that NF-κB signaling pathway is in abnormal activation state in MZL. Bortezomib, a proteasome inhibitor targeting NF-κB pathway, has a promising therapeutic prospect in relapsed and refractory MZL. The goal of our trial is to assess the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.
A prospective study showed that a mild reduction in AT levels (70%-80%) was associated with the recurrence of no incentive VTE. Subsequent studies defined mild AT deficiency as less than the 5th percentile of the normal range to further verify that mild AT deficiency is a risk factor for VTE recurrence. Many retrospective studies have also shown that the activities of AT-Ⅲ, PC and PS are related to the occurrence and recurrence of VTE and DVT. Taking the lower limit of the normal reference value as the criterion for judging the lack of anticoagulant protein activity, Zhu Tienan et al. found that the lack of activity of AT, PC, and PS in normal people were 1.15%, 1.49%, and 2.29%, respectively. Fang Biqian et al. found 277 cases of VTE. Among the cases found that the lack of activity of AT, PC, and PS were 16.00%, 17.45%, and 17.09%, respectively. That is, the lack of activity of the three anticoagulant proteins in VTE patients was about 10 times higher than that of normal people. Chinese scholars from Taiwan, Hong Kong and Shanghai also found that the total lack of three anticoagulant proteins of AT-Ⅲ, PC and PS exceeds 15% in Western countries, suggesting that the etiological composition of venous thromboembolism in the Chinese population may be similar to that of Western countries. Different, reflecting that anticoagulant protein deficiency plays an important role in the pathogenesis of VTE patients in China. Compared with factor V Leiden mutation and prothrombin 20210A mutation, the most common thrombosis in Asian population is antithrombin Ⅲ (AT-Ⅲ), protein C (protein C, PC) and protein S (protein S, PS), etc. Defects of anticoagulant protein. When the hypercoagulable state caused by anticoagulant protein deficiency is induced by certain risk factors for thrombosis, such as pregnancy, oral contraceptives, fractures, long-term immobilization, etc., it can lead to the occurrence of VTE. When PICC is implanted in patients with AT-Ⅲ, PC and PS activity defects, whether PICC indwelling will become a predisposing factor of thrombosis is not yet known.

It has been reported that the severity of CVC-related thrombosis in patients with AT-Ⅲ deficiency after CVC catheterization is higher than that of the normal group. Nowak-Göttl et al. showed that PC and PS genetic defects are related to catheterization in children Thrombosis plays an important role. In 2016, a systematic review showed that the risk of DVT related to more than one anticoagulant defect increased by 3.20 times. PC defects can increase the incidence of CVC-related DVT in children. Our preliminary study of this subject found that the lack of anticoagulant protein in PICC-RVT patients was higher than that in non-PICC-RVT patients.
All participants will be monitored with electrocardiogram, pulse oximeter , non-invasive blood pressure. The fasting period of the patients was 8 hours. The participants were randomly divided into two groups by the auxiliary health personnel using the closed envelope draw method. After the participants were taken to the operating room, their files were checked, consent for the study was obtained, and the Apfel score was noted. Participants were started on intravenous crystalloid fluid infusion at 8ml/kg/hour. After induction of general anesthesia with 0.03mg/kg midazolam, 2-2.5 mg/kg propofol, 1 µg/kg remifentanil, 0.6 mg/kg rocuronium, the participants were intubated and connected to the anesthesia machine, with sevoflurane and maintenance administered at minimum alveolar concentration 1.3. was achieved with remifentanil infusion. After the participants were connected to the anesthesia device, the tidal volume was adjusted to 7 ml/kg, respiratory rate 12-14/min, positive end-expiratory pressure 5 cmH2O, flow 2 liter/min, Fraction of inspired oxygen 30% in Group I and 80% in Group 2. Gastric fluid and air were aspirated from the participants using an orogastric tube. The participants' vitals were monitored intraoperatively at 5-minute intervals and recorded every 15 minutes. Intra-abdominal pressure was kept between 10-12 mmHg. Approximately 15 minutes before the end of the surgical procedure, remifentanil infusion was stopped, and 1 g paracetamol and 50 mg dexketoprofen i.v. were administered as postoperative analgesics was given. No narcotic analgesics were given. At the end of the operation, exsufflation was performed before the trocars were removed and the intra-abdominal pressure was allowed to return to normal. The surgical team was given bupivacaine to administer 15 mg per trocar site. While the last few skin stitches were being placed, sevoflurane was discontinued in all participants and they were switched to 100% oxygen. Muscle relaxant antagonism was achieved with sugammadex (2 mg/kg) in both groups. The patients were extubated and monitored for 1 hour postoperatively in the recovery unit. All patients were given 2 liter/min O2 in the recovery unit. In case of nausea and vomiting, the Nausea Vomiting Score is noted and 4 mg of ondansetron i.v. is given to patients with moderate to severe nausea and vomiting. Participants requiring additional analgesics were given 100 mg tramadol. Postoperative 24-hour nausea and vomiting was monitored in the patient's hospitalization ward. The participants with nausea and vomiting during the 24-hour follow-up were learned from the follow-up doctor and noted on the follow-up forms. During the ward follow-up, patients with nausea were given 4mg of ondansetron.
PROBLEM TO BE SOLVED: To prepare a composition for hair, capable of raising the absorption amount of an ultraviolet ray absorber in the hair, protecting the hair from the damage with the ultraviolet rays and capable of suppressing the dryness and looseness and imparting the moistness and flexibility to the hair. SOLUTION: This composition for hair is obtained by enclosing an ultraviolet ray absorber in a vesicle of a cationic surfactant represented by the formula (R1 and R2 are each a 12-22C alkyl; X is a halogen) and blending the resultant vesicle therein. 2-Ethylhexyl p-methoxycinnamate, etc., are exemplified as the ultraviolet ray absorber and enclosed in an amount of 0.1-2wt.% therein. A water-soluble substance containing a humectant or a nutrient ingredient can further be enclosed in an amount of 0.1-30wt.% and blended therein. The vesicle of the cationic surfactant enclosing the water-soluble substance and the vesicle enclosing the ultraviolet ray absorber can be used in combination to improve the state of the hair. The composition can be prepared as a composition for washing hair such as a shampoo, a rinse, a conditioner, a hair mist or a hair spray, a treatment composition or a hairdressing composition.
Compsns. for treating peripheral vascular disorders in humans with inadequate circulation in the extremities, contain sufficient of a PGE1 cpd. (I) to alleviate pain when the patient is resting, or to start healing of ulcers. The compsns. are administered by other than the intra-arterial route. (I) may be a PGE1 salt; a lower alkyl, esp. methyl, ester or the amide and can be formulated as a saline or aq. soln. or as a coated tablet. The dangers and difficulties of intra-arterial injection are avoided, and (I) does not have to be passed through the lungs (where it undergoes rapid metabolism to relatively inactive cpds.,) before reaching the affected links. The relief of pain often lasts for several weeks after the end of the treatment.
The present invention provides a pair of odor free shoe pads and a production method thereof. Each odor free shoe pad is composed of a surface layer, a middle layer and a base layer, wherein any one surface or two surfaces between the middle layer and the surface layer are printed with the compounding agent; any one surface or two surfaces between the base layer and the middle layer are printed with the compounding agent; the compounding agent is obtained in a method that alum, one or two kinds of anhydrous cupric sulfate, anhydrous cupric sulfate and soft water are mixed into liquid which is mixed with acetylsalicylic acid and viscous agent to be heated into a viscous state. By the method of the present invention and after the compounding agent is printed among the surface layer, the middle layer and the base layer, the shoe pad has firm adhesiveness, firmness, durability, and lasting drug effect of the compounding agent. The compounding agent which comprises acetylsalicylic acid, alum, etc. can prevent bacteria, remove foot osmyl and absorb foot sweat. The shoe pad of the present invention has the advantages of simple manufacture method, low cost and suitable generalization.
MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
A 63-year-old man with decompensated liver cirrhosis was admitted for treatment of stomal hemorrhage. Eighteen months earlier, he was diagnosed with rectal and sigmoid colon cancer with multiple lymph node metastases, and he underwent colostomy surgery and postoperative chemotherapy. Sixteen months after the surgery, his stoma began to bleed repeatedly, and he required frequent blood transfusions. A contrast-enhanced computed tomography revealed ectopic varices around the stoma. We considered surgical or endoscopic treatment; however, these approaches would have been technically difficult in this patient. The patient was treated with partial splenic embolization to improve thrombocytopenia and portal hypertension. After two-stage partial splenic embolization, the platelet counts increased, and the concentration of the liver fibrosis marker, Mac-2 binding protein, decreased. In addition, blood flow in the stomal varices decreased, with no recurrence of bleeding. This is a case of recurrent hemorrhage from stomal varices that was successfully treated with partial splenic embolization in a patient with liver cirrhosis. There are no guidelines for hemorrhage from ectopic varices. PSE may present potential utility as a treatment for ectopic variceal bleeding, such as stomal varices.
A full-automatic biochemical analyzer, and a sampling device and a sampling method thereof. The sampling device comprises: a frame (100), a horizontal motion system, a vertical motion system, a sampling component and a force transmission guide rail (101). The horizontal motion system comprises a first stepping motor (116), the vertical motion system comprises a second stepping motor (103), and the first stepping motor (116) and the second stepping motor (103) are respectively fixedly mounted on the frame (100). The sampling component comprises a sampling needle pressing block (114) and a sampling needle (111). The stepping motors (116, 103) are both fixed on the frame. The analyzer is smart in motion, low in cost, and compact in structure, and meanwhile has the functions of open sampling and closed puncturing sampling and the function of conveying samples to the specified position.
A method of increasing the solubility of flavonols comprises mixing together a flavonol-containing composition and an anthocyanin-containing composition. The flavonol may be quercetin, kaempferol or myricetin or glycosides thereof and the anthocyanin may be malvidin, cyanidin, delphinidin, paeonidin, pelargonidin, polymeric anthocyanins or leucocyanidins or glycosides thereof. The anthocyanin-containing composition may be a fruit juice, vegetable extract, wine or dealcoholised wine. The flavonol-containing composition, which may be an ethanolic solution, may be dissolved in an aqueous anthocyanin-containing solution. A dry composition may be prepared from the resulting solution. The compositions prepared by mixing a flavonol-containing composition and an anthocyanin-composition may further comprise one or more of anti-oxidants, flavouring agents, sweeteners, vitamins, minerals and aspirin.
Managing difficult airway is critical for anesthesia-related morbidity and mortality. Fiberoptic laryngoscope is a reliable tool for endotracheal intubation in difficult airway cases (Modified Mallampatti III\&IV), but always there is difficulty to visualize the glottis due to airway tendency to collapse, classically a specific fiberoptic airway with a side way is used and it may added head tilt chin lift jaw thrust. A new technique utilizing sevoflurane anesthesia to maintain the respiratory drive without exposing the patient to the stress of the awake airway instrumentation. Simultaneous utilization of both Macintosh curved laryngoscope and Fiberoptic bronchoscope during Endotracheal intubation (ETT) will be examined for the efficacy during difficult airway management.

All patients should be examined preoperatively for the scoring Modified Mallampati or non tongue protrusion mallampati (NT-MMT) airway score. The pharyngeal structures were then evaluated and the best view (lowest class) was recorded. The classification follows m-MMT and is as follows: class 1, full visibility of tonsils, uvula, and soft palate; class 2, visibility of hard and soft palate, upper portion of tonsils and uvula; class 3, visibility of the soft and hard palate and base of the uvula; and class 4, visibility of only the hard palate, class III or IV patients were included in the study. Inhalational anesthesia use maintains the respiratory drive of the patient allowing less stressful technique.
PURPOSE:A carcinostatic adjuvant, containing an extract crude drugs consisting of Astragali Radix, Peony root, Cnidium, etc. with water or an aqueous solvent as an active constituent, and capable of enhancing the carcinostatic action of mitomycin C and reducing the leukopenia. CONSTITUTION:A carcinostatic adjuvant prepared by extracting a mixture of four crude drugs consisting of Astragali Radix, Peony root, Cnidium and Atractylodes with water or an aqueous solvent, e.g. ethanol, or extracting the respective crude drugs, mixing the respective extracts, using the resultant extract directly or adding an excipient or assistant, etc. thereto, for formulating the resultant mixture into a dosage form of powder, granule, tablet, capsule, etc. The extraction is carried out preferably at room temperature or under heating at 50-100 deg.C. The mixing ratio of the above-mentioned crude drugs is preferably as follows in the order mentioned: 1.0-4.0, 1.0-4.0, 1.0-4.0 and 1.0-4.0.
<P>PROBLEM TO BE SOLVED: To facilitate scoring of a radiograph.  <P>SOLUTION: In the method for radiographic scoring of a radiographic image, at least one region of interest is determined. Each of the determined regions of interest is displayed in close proximity to a number of reference stages each having an associated score. For each region of interest, a reference stage image best matching the displayed region of interest is selected and the score number associated with the selected reference stage image is associated with the region of interest. Score numbers retained for each of the regions of interest are combined to form the score number of the radiographic image.  <P>COPYRIGHT: (C)2003,JPO
The dose of placebo will be given twice per day just prior to or during a feed at 0.2 ml/kg. To be prescribed and given following enrolment.
In addition to midwifery care, training content, training videos and brochure-supported training on NST will be provided. The NST device will be inserted and, to be standard, 5 minutes after the procedure begins, the volume of the fetal heart sound coming from the device will be increased during the NST recording and the fetal heart sound will be ensured to continue. The pregnant woman who will be transferred will rest for about 2 minutes.